Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline 0.9% Clear all

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more

Conditions: Pain, Virtual Reality, Placebo
Interventions: Naloxone, Saline; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Respiratory Distress Syndrome, Infections
Interventions: Rhu-pGSN, normal saline; Drug
Lead sponsor: BioAegis Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more

Conditions: Surgical Site Infection
Interventions: IrriSept System, No Intervention - Standard of Care (SoC) only; Device · Other
Lead sponsor: Irrimax Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more

Conditions: Papulopustular Rosacea
Interventions: Cromolyn Sodium, Normal Saline; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Brain Injuries, Traumatic
Interventions: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD), 7.5% Hypertonic Saline (HS), 0.9% Normal Saline (NS); Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • San Diego, California + 7 more

Conditions: Schistosomiasis
Interventions: Placebo, Sm-TSP-2/Alhydrogel, Sm-TSP-2/Alhydrogel/GLA-AF; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain, Postoperative, Femur Fracture
Interventions: Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Colonoscopy, Adjunct Anesthesia Medication
Interventions: Diphenhydramine, Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Fever
Interventions: Ibuprofen, Normal Saline; Drug · Other
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: Orlando, Florida • St Louis, Missouri • Greensboro, North Carolina + 4 more

Conditions: Plantar Fasciitis
Interventions: Injection of 1.0 cc of 0.9% Saline, Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension; Procedure
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Advanced Solid Tumors
Interventions: palifosfamide-tris, Normal Saline; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Dallas, Texas • Houston, Texas • San Antonio, Texas

Conditions: Neuropathic Pain
Interventions: Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Heart Disease
Interventions: Exendin-9, GLP-1, saline; Drug · Other
Lead sponsor: David Dalessio; Other
Eligibility: 40 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Non-small Cell Lung Cancer
Interventions: Pralatrexate, Erlotinib, Vitamin B12, Folic Acid; Drug · Dietary Supplement
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Bakersfield, California • San Diego, California • Port Saint Lucie, Florida + 12 more

Conditions: End Stage Heart Disease, Right Ventricular Dysfunction
Interventions: inhaled nebulized milrinone; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Community-acquired Infection
Interventions: GSK2251052 750 mg, GSK2251052 1500 mg, GSK2251052 1500 mg BID, GSK2251052 2250 mg, GSK2251052 3000 mg, GSK2251052 0.9% saline; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Seattle, Washington

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: NI112, Placebo; Drug
Lead sponsor: Sachi Bioworks Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Bunion, Hallux Valgus
Interventions: SKY0402, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 17
States / cities: Los Angeles, California • Santa Clarita, California • New Haven, Connecticut + 14 more

Conditions: Gender Dysphoria, Opioid Use, Pain, Postoperative
Interventions: Ropivacaine 0.2% Injectable Solution, Saline (0.9%); Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pain, Referred
Interventions: Bupivacaine, Morphine, Fentanyl, Epinephrine, Saline solution; Drug · Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 17 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Traumatic Brain Injury
Interventions: autologous bone marrow mononuclear cells, Placebo Infusion; Biological · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 5 Years to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona • Houston, Texas

Search by objective public record fields.

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

Neural Correlates of Hypoalgesia Driven by Observation

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Irrisept Versus Standard of Care in the Prevention of Surgical Site Infections

An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures

Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis

Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

Effect of GLP-1 on Postprandial Lipid Metabolism

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study

A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)

Study of Postoperative Analgesia in Bunionectomy

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

The Effect of Pectoral Blocks on Perioperative Pain in Gender Affirmation Top Surgery

Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury